Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 18/20 | 0.41 |
| ▸ | ATRIP | Q8WXE1 | 16/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 9/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 9/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464382 | 1.00 | PIK3C3 (0.42) | PIK3C3ATRATRIPCHEK1PDCD1 | |
| SCHEMBL19951347 | 1.00 | PIK3C3 (0.42) | PIK3C3ATRATRIPCHEK1PDCD1 | |
| SCHEMBL19951353 | 0.89 | ATR (0.42) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL29464489 | 0.89 | ATR (0.42) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL19951355 | 0.89 | ATR (0.42) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL19951337 | 0.87 | ATR (0.42) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL19951339 | 0.87 | ATR (0.42) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL29464360 | 0.87 | ATR (0.42) | ATRATRIPCHEK1PDCD1CD274 | |
| SCHEMBL23770615 | 0.83 | ATR (0.43) | PIK3C3ATRATRIPRAF1BRAF | |
| SCHEMBL19951310 | 0.81 | NMT1 (0.45) | MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | claimed |
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | claimed |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | claimed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | claimed |
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | PIK3C3 3261/4885ATR 4338/4885ATRIP 3348/4885 |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | PIK3C3 3261/4885ATR 4338/4885ATRIP 3348/4885 |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | PIK3C3 3261/4885ATR 4338/4885ATRIP 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.